The voting results and auditor ratification are routine. The more notable indicator is the DEFA14A cross-filing showing Executive Chair Hoerter became a consultant and lost independence on May 1—a governance change typical of a transition toward non-founder management. Monitor for any subsequent Form 4 filings from Hoerter or changes in strategic direction. For now, the event is neutral for the stock.
Price Chart
Executive Summary
MBX Biosciences held its 2026 annual meeting on June 4, 2026, where stockholders elected Class II directors Patrick J. Heron and Edward T. Mathers and ratified Ernst & Young as the independent auditor. This 8-K reports routine governance results with no material financial disclosures; the nearby DEFA14A cross-filing disclosed Executive Chair Steven L. Hoerter's consulting agreement and loss of independent status as of May 1, 2026, signaling a governance change that warrants monitoring.
Key Facts
- Annual Meeting held June 4, 2026; two Class II director nominees (Patrick J. Heron and Edward T. Mathers) elected for three-year terms ending 2029
- Patrick J. Heron received 35,007,623 votes 'for' vs 4,579,129 'withheld'; Edward T. Mathers received 31,983,223 'for' vs 7,603,529 'withheld'
- Ratification of Ernst & Young as auditor for FY2026 passed with 43,713,693 'for', 1,946 'against', 1,946 'abstain'
- Outstanding shares at record date: 47,570,485
- Cross-filing DEFA14A (May 8, 2026) disclosed that Executive Chair Steven L. Hoerter entered a consulting agreement on May 1, 2026, resigned from the Audit Committee, and is no longer independent under Nasdaq rules; Edward T. Mathers joined the Audit Committee
Financial Impact
No financial impact from this filing.
Risk Factors
- Loss of independent chair may raise governance concerns for some institutional investors.
- Consulting arrangement with the Executive Chair could signal management transition or succession planning.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-258417 |
| Document: 0001193125-26-258417-index-headers.html | 0001193125-26-258417 |
| Document: 0001193125-26-258417-index.html | 0001193125-26-258417 |
| Document: 0001193125-26-258417.txt | 0001193125-26-258417 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 3 | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $50.29 (−0.34%) |
Oct 22, 2026 4d ago | 8-K | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $50.29 (−0.34%) |
Aug 27, 2026 8w ago | Press Release | $66.39 $63.00 | ▼ −5.11% | ▼ −4.88% | $50.29 (−24.25%) |
Aug 17, 2026 10w ago | 144 | $68.25 $66.52 | ▼ −2.53% | ▼ −1.86% | $50.29 (−26.32%) |
Aug 6, 2026 11w ago | 8-K | $67.11 $67.82 | ▲ +1.06% | ▲ +0.45% | $50.29 (−25.06%) |
Jun 12, 2026 19w ago | 8-K | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $50.29 (+41.62%) |
Jun 12, 2026 19w ago | Press Release | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $50.29 (+41.62%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $50.29 (+35.01%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $50.29 (+35.01%) |
Jun 10, 2026 19w ago | 144 | $30.99 $37.25 | ▲ +20.20% | ▲ +18.50% | $50.29 (+62.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers